These columns originally appeared in BioWorld Today. They are reprinted here with the permission of Thomson BioWorld, www.bioworld.com. If you have comments or relevant experiences you would like to share, or if you want to argue the points raised, please write to bioworld.letters@thomson.com. Selected letters will be posted on the BioWorld site. Note that comments are subject to editing for clarity and length. Comments also can be sent directly to Dr. Robbins-Roth at biogodess@earthlink.net.
As The BioWorld Turns, Part II:
Slimming Down With Brownies? -- April 9, 2007
As Biotech Turns:
Fumbling, Bumbling And Posh Spice -- March 26, 2007
Location, Location, Location:
Ceregene Bets on Better Delivery -- March 12, 2007
Getting Closer to Nature:
The BrainCells Way -- February 26, 2007
Is FIPCO Only Way To Go? Try Thinking 'Small Ball' -- February 12, 2007
Research at Gladstone Institute Translating Into New Products -- January 16, 2007
Unintended Consequences:
Mother Nature vs. Innovation -- January 2, 2007
Weak Dollar Good For Biotech:
Outsourcing Trend May Reverse -- December 18, 2006
Will 2007 Have Tidings Of Joy?
Some Thoughts On Next Year -- December 4, 2006
Filling The Pipeline:
'Early Stage' Firm Varies In Eyes Of Beholder -- November 20, 2006
Smell Of Dollars Burning On Breeze Of Pre-Election
-- November 6, 2006
Considering Brain Disease,
It's Time For New March Of Dimes -- October 23, 2006
For Biotech CEOs,
Does VC Grass Seem Greener? -- October 10, 2006
Fall Fun With Finances:
School's Back In Session -- September 25, 2006
Still Turning: Racial Profiling,
Harassment, VC Execs Get Hip -- August 1, 2006
As The BioWorld Turns:
From White Biotech To Stem Cell Fun -- July 31, 2006
When Frank Talks,
Everyone Listens But Will They Act? -- July 5, 2006
Mining Minds Of Doctors
For Better Predicting Drug Market -- June 19, 2006
Biotechnology Soap Opera:
FDA, Sex, Politics, Religion -- June 5, 2006
High-Priced Drugs Causing Angst;
Genzyme Stands Pat -- May 22, 2006
How Frustrated Firm ReqMed
Created New Biotech Strategy -- May 8, 2006
How Juvaris Found New Path,
Gathered Funds, Moved Ahead -- April 24, 2006
Four Points Of Concern
As Biotechnology Grows -- April 10, 2006
Need Public Market Access?
Go Knock On Heaven's Door (Corp.) -- March 27, 2006
A Kinder, Gentler Place
For Biotech Hallmark: Start-ups -- March 13, 2006
Love, Gambling And Biotech:
Side Effects Of CNS Drugs -- February 27, 2006
Deal Terms Reward Products:
No Surprise From 2005 Trends -- February 13, 2006
Much Like Peter Pan,
Big Pharma Won't Grow Up -- January 30, 2006
Biotech's Redemption Chance:
Make Drugs, Foster Community -- January 17, 2006
Biotech & Business Ethics:
Time To Face Up To Reality -- December 12, 2005
For All Biotech's Forward
Progress, Issues Remain -- November 4, 2005
Pricing, Data Leaks, Safety:
Biotech's Simmering Stew -- November 3, 2005
Australian Biotechs Should
Rethink Financing Structure -- September 28, 2005
The List: Innovative Models On
Which To Build Biotech -- August 3, 2005
Building Biotechnology But
Not Via Biotech Companies -- August 2, 2005
BIO's Past President Mulls
Biotech's Path Into Future -- June 20, 2005
Broken? Readers Comment On Biotechnology Hurdles -- May 31, 2005
Biotech Model Broken;
Now What Can Be Done About It? -- May 3, 2005
Lower IPO Valuations Quashing Early VC Biotechnology Funding -- May 2, 2005
A David vs. Goliath Biotech Story, With Goliath Winning -- April 8, 2005
Survival Of Fittest In 2005 For Biotechnology Firms -- March 14, 2005
 |
 |
Recap BioWorld Sedar Wall Street Journal Edgar
BioMedNet BioSpace BIO